% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Biel:162705,
      author       = {Biel, Davina and Brendel, Matthias and Rubinski, Anna and
                      Bürger, Katharina and Janowitz, Daniel and Dichgans, Martin
                      and Franzmeier, Nicolai},
      collaboration = {Initiative, Alzheimer’s Disease Neuroimaging},
      title        = {{T}au-{PET} and in vivo {B}raak-staging as prognostic
                      markers of future cognitive decline in cognitively normal to
                      demented individuals.},
      journal      = {Alzheimer's research $\&$ therapy},
      volume       = {13},
      number       = {1},
      issn         = {1758-9193},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DZNE-2021-01362},
      pages        = {137},
      year         = {2021},
      note         = {CC BY},
      abstract     = {To systematically examine the clinical utility of tau-PET
                      and Braak-staging as prognostic markers of future cognitive
                      decline in older adults with and without cognitive
                      impairment.In this longitudinal study, we included 396
                      cognitively normal to dementia subjects with
                      18F-Florbetapir/18F-Florbetaben-amyloid-PET,
                      18F-Flortaucipir-tau-PET and ~ 2-year cognitive follow-up.
                      Annual change rates in global cognition (i.e., MMSE, ADAS13)
                      and episodic memory were calculated via linear-mixed models.
                      We determined global amyloid-PET (Centiloid) plus global and
                      Braak-stage-specific tau-PET SUVRs, which were stratified as
                      positive(+)/negative(-) at pre-established cut-offs,
                      classifying subjects as
                      Braak0/BraakI+/BraakI-IV+/BraakI-VI+/Braakatypical+. In
                      bootstrapped linear regression, we assessed the predictive
                      accuracy of global tau-PET SUVRs vs. Centiloid on subsequent
                      cognitive decline. To test for independent tau vs. amyloid
                      effects, analyses were further controlled for the contrary
                      PET-tracer. Using ANCOVAs, we tested whether more advanced
                      Braak-stage predicted accelerated future cognitive decline.
                      All models were controlled for age, sex, education,
                      diagnosis, and baseline cognition. Lastly, we determined
                      Braak-stage-specific conversion risk to mild cognitive
                      impairment (MCI) or dementia.Baseline global tau-PET SUVRs
                      explained more variance (partial R2) in future cognitive
                      decline than Centiloid across all cognitive tests (Cohen's d
                      ~ 2, all tests p < 0.001) and diagnostic groups.
                      Associations between tau-PET and cognitive decline remained
                      consistent when controlling for Centiloid, while
                      associations between amyloid-PET and cognitive decline were
                      non-significant when controlling for tau-PET. More advanced
                      Braak-stage was associated with gradually worsening future
                      cognitive decline, independent of Centiloid or diagnostic
                      group (p < 0.001), and elevated conversion risk to
                      MCI/dementia.Tau-PET and Braak-staging are highly predictive
                      markers of future cognitive decline and may be promising
                      single-modality estimates for prognostication of
                      patient-specific progression risk in clinical settings.},
      keywords     = {Aged / Alzheimer Disease: complications / Alzheimer
                      Disease: diagnostic imaging / Amyloid beta-Peptides /
                      Cognitive Dysfunction: diagnostic imaging / Humans /
                      Longitudinal Studies / Positron-Emission Tomography /
                      Prognosis / tau Proteins / Alzheimer’s disease (Other) /
                      Amyloid-PET (Other) / Braak-staging (Other) / Conversion
                      risk (Other) / Tau-PET (Other) / Amyloid beta-Peptides (NLM
                      Chemicals) / tau Proteins (NLM Chemicals)},
      cin          = {AG Höglinger 2},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34384484},
      pmc          = {pmc:PMC8361801},
      doi          = {10.1186/s13195-021-00880-x},
      url          = {https://pub.dzne.de/record/162705},
}